A Single-center, Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, 4-way Cross-over Study to Assess Next-day Driving Performance Following Single and Multiple Evening Administrations of ACT-541468 in Middle-aged and Elderly Subjects
Latest Information Update: 22 Apr 2022
At a glance
- Drugs Daridorexant (Primary) ; Zopiclone
- Indications Insomnia
- Focus Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 14 Apr 2022 Results examining driving performance following administration of daridorexant, published in the Clinical Pharmacology and Therapeutics
- 18 Mar 2022 Results presented at the 123rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 30 Oct 2019 Status changed from recruiting to completed.